Stereotactic body radiotherapy with 50 Gy in 10 fractions for unresectable liver metastasis

Objective To explore the clinical efficacy of stereotactic body radiotherapy (SBRT) for the treatment of patients with unresectable liver metastasis.

Methods Data of 28 patients with unresectable liver metastases were retrospectively analyzed. All patients were admitted to the Shanghai East Hospital from March 2018 to November 2019. Patients underwent 4D-CT or respiration gating for CT simulation. The prescription dose for the liver metastasis was 50 Gy in 10 fractions.

Results All patients successfully completed the SBRT treatment. The median overall survival was 7.4 months. The six months and one-year survival rates were 95.0% and 70.1%, respectively. The local control rate for one year was 92.2%. The most common toxicity was grade Ⅰ or Ⅱ nausea, poor appetite, and abdominal pain. No grade Ⅲ or worse toxicity was found.

Conclusions SBRT with 50 Gy in 10 fractions is a safe and effective treatment for patients with unresectable liver metastasis.